Cel-Sci Corp. (CVM)

06:33 AM

Cel-Sci Corp [AMEX: CVM] Sees Increase in Stock Value - knoxdaily.com

06:33 AM

Apr 24, 2025

US biotech seeks Saudi approval for cancer treatment - Arabian Gulf Business Insight | AGBI

Apr 24, 2025

Apr 23, 2025

CEL-SCI to seek Saudi approval for cancer treatment - Investing.com

Apr 23, 2025

Apr 23, 2025

CEL-SCI Corp To File For Regulatory Approval Of Multikine In Saudi Arabia - marketscreener.com

Apr 23, 2025

Apr 23, 2025

CEL-SCI's Cancer Drug Eyes Breakthrough Status in Saudi Arabia as MENA Cancer Cases Set to Double - Stock Titan

Apr 23, 2025

Apr 23, 2025

Market Momentum Report: Cel-Sci Corp (CVM)’s Positive Close at 0.27 - DWinneX

Apr 23, 2025

Apr 23, 2025

Its Stock Has Paid Off Big Time For Cel-Sci Corp - Sete News

Apr 23, 2025

Apr 22, 2025

An Analysis of Cel-Sci Corp (CVM)’s Potential Price Growth - knoxdaily.com

Apr 22, 2025

Apr 22, 2025

Parsons Corp [PSN] Investment Appeal on the Rise - knoxdaily.com

Apr 22, 2025

Apr 22, 2025

Cel-Sci Corp (CVM) presents a great opportunity, but the stock is slightly overvalued - uspostnews.com

Apr 22, 2025

Apr 22, 2025

StockNews.com Initiates Coverage on CEL-SCI (NYSE:CVM) - Defense World

Apr 22, 2025

Apr 11, 2025

CEL-SCI's Multikine (CVM) Shows Promising Survival Rates in Head and Neck Cancer Study - GuruFocus

Apr 11, 2025

Apr 11, 2025

12 Health Care Stocks Moving In Friday's Intraday Session - Benzinga

Apr 11, 2025

Apr 09, 2025

CVM stock touches 52-week low at $0.18 amid sharp annual decline - Investing.com Australia

Apr 09, 2025

Apr 09, 2025

CVM stock touches 52-week low at $0.18 amid sharp annual decline By Investing.com - Investing.com South Africa

Apr 09, 2025

Apr 08, 2025

Breakthrough Cancer Study: New Data Shows 306% Survival Boost for Multikine Treatment - Stock Titan

Apr 08, 2025

Apr 06, 2025

CEL-SCI (NYSE:CVM) Now Covered by StockNews.com - Defense World

Apr 06, 2025

Mar 31, 2025

CVM stock touches 52-week low at $0.23 amid sharp annual decline By Investing.com - Investing.com South Africa

Mar 31, 2025

Mar 31, 2025

CVM stock touches 52-week low at $0.23 amid sharp annual decline - Investing.com Australia

Mar 31, 2025

Mar 29, 2025

CEL-SCI (NYSE:CVM) Earns Sell Rating from Analysts at StockNews.com - Defense World

Mar 29, 2025

Mar 24, 2025

Breakthrough: New Cancer Drug Delivers 95% Quality of Life Improvement for Head & Neck Patients - Stock Titan

Mar 24, 2025

Mar 21, 2025

CVM stock touches 52-week low at $0.26 amid sharp annual decline - Investing.com Australia

Mar 21, 2025

Mar 21, 2025

CVM stock touches 52-week low at $0.26 amid sharp annual decline By Investing.com - Investing.com South Africa

Mar 21, 2025

Mar 21, 2025

Cel-Sci Corp (CVM) Volatility Hits 12.01%: What Good Investors Need To Be Aware Of - Stocks Register

Mar 21, 2025

Mar 18, 2025

CEL-SCI announces closing of $2.5 million offering -March 18, 2025 at 05:23 pm EDT - Marketscreener.com

Mar 18, 2025

Mar 18, 2025

CEL-SCI Secures $2.5M Funding: Major Push for FDA-Designated Cancer Immunotherapy - StockTitan

Mar 18, 2025

Mar 18, 2025

Why Harrow Shares Are Trading Higher By 23%; Here Are 20 Stocks Moving Premarket - Benzinga

Mar 18, 2025

Mar 17, 2025

CEL-SCI Secures Critical Funding for FDA-Approved Head & Neck Cancer Treatment Study - StockTitan

Mar 17, 2025

Mar 17, 2025

CEL-SCI advances in head and neck cancer treatment study - Investing.com

Mar 17, 2025

Mar 17, 2025

12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga

Mar 17, 2025

Mar 17, 2025

CEL-SCI advances in head and neck cancer treatment study By Investing.com - Investing.com UK

Mar 17, 2025

Mar 17, 2025

CEL-SCI’s Head and Neck Cancer Registration Study Protocol Clears FDA Review—in Talks with Potential Partners Interested in Commercialization of Multikine - Yahoo Finance

Mar 17, 2025

Mar 17, 2025

CEL-SCI Cancer Treatment Shows 73% Survival Rate, FDA Clears Path to Market - Stock Titan

Mar 17, 2025

Mar 15, 2025

Cel-Sci Corp (CVM) Recovers 5.85% From Low: Are We There Yet? - Stocks Register

Mar 15, 2025

Mar 14, 2025

Major Breakthrough: JAMA Study Shows Multikine Triples Survival Rates in Head and Neck Cancer - StockTitan

Mar 14, 2025

Mar 13, 2025

CEL-SCI (NYSE:CVM) Coverage Initiated at StockNews.com - Defense World

Mar 13, 2025

Mar 10, 2025

CVM stock touches 52-week low at $0.31 amid sharp annual decline - Investing.com Australia

Mar 10, 2025

Mar 10, 2025

CVM stock touches 52-week low at $0.31 amid sharp annual decline By Investing.com - Investing.com South Africa

Mar 10, 2025

Mar 07, 2025

CEL-SCI Announces That NYSE MKT Granted an Extension to Regain Compliance - AOL.com

Mar 07, 2025

Mar 06, 2025

CVMCEL-SCI Corp Latest Stock News & Market Updates - Stock Titan

Mar 06, 2025

Mar 05, 2025

4 Biotech Stocks To Watch: CVM, NKGN, NBIO, IMUX - DRP Journal

Mar 05, 2025

Feb 28, 2025

CVM Stock Hits 52-Week Low at $0.33 Amid Steep Annual Decline - Investing.com Australia

Feb 28, 2025

Feb 27, 2025

CVM Stock Hits 52-Week Low at $0.33 Amid Steep Annual Decline By Investing.com - Investing.com South Africa

Feb 27, 2025

Feb 20, 2025

CEL-SCI advances Multikine study for head and neck cancer - Investing.com

Feb 20, 2025

Feb 20, 2025

CEL-SCI advances Multikine study for head and neck cancer By Investing.com - Investing.com UK

Feb 20, 2025

Feb 20, 2025

CEL-SCI to Initiate Multikine Confirmatory Phase 3 Cancer Trial -February 20, 2025 at 08:06 am EST - Marketscreener.com

Feb 20, 2025

Feb 20, 2025

CEL-SCI to Initiate Multikine Confirmatory Phase 3 Cancer Trial - Yahoo Finance

Feb 20, 2025

Feb 20, 2025

Can This Cancer Drug Triple Patient Survival Rates? New Trial Holds Answer - Stock Titan

Feb 20, 2025

Feb 19, 2025

CEL-SCI Reports Fiscal Q1 2025 Financial Results: Multikine Shows Pre-Surgical Tumor Elimination and Regression in Just 3 Weeks - BioSpace

Feb 19, 2025

Feb 18, 2025

StockNews.com Begins Coverage on CEL-SCI (NYSE:CVM) - Armenian Reporter

Feb 18, 2025

Feb 17, 2025

CEL-SCI (NYSE:CVM) Now Covered by Analysts at StockNews.com - Defense World

Feb 17, 2025